The DOI matches its Crossref record; 216 of the 216 references it cites were found in a registry or an index.
Cognitive decline in Parkinson disease
Open accessAbstract
Dementia is a frequent problem encountered in advanced stages of Parkinson disease (PD). In recent years, research has focused on the pre-dementia stages of cognitive impairment in PD, including mild cognitive impairment (MCI). Several longitudinal studies have shown that MCI is a harbinger of dementia in PD, although the course is variable, and stabilization of cognition - or even reversal to normal cognition - is not uncommon. In addition to limbic and cortical spread of Lewy pathology, several other mechanisms are likely to contribute to cognitive decline in PD, and a variety of biomarker studies, some using novel structural and functional imaging techniques, have documented in vivo brain changes associated with cognitive impairment. The evidence consistently suggests that low cerebrospinal fluid levels of amyloid-β 42, a marker of comorbid Alzheimer disease (AD), predict future cognitive decline and dementia in PD. Emerging genetic evidence indicates that in addition to the APOE*ε4 allele (an established risk factor for AD), GBA mutations and SCNA mutations and triplications are associated with cognitive decline in PD, whereas the findings are mixed for MAPT polymorphisms. Cognitive enhancing medications have some effect in PD dementia, but no convincing evidence that progression from MCI to dementia can be delayed or prevented is available, although cognitive training has shown promising results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Moreover there are several candidate genetic risk factors that overlap for AD and PD, most notably APOE and MAPT [127].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
MDS clinical diagnostic criteria for Parkinson’s disease
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders · doi:10.1002/mds.26424 · Cited by 7,653
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Clinical diagnostic criteria for dementia associated with Parkinson’s disease
Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., Broe, G. A., Cummings, J., Dickson, D. W., Gauthier, S., et al. (2007) · Movement Disorders · doi:10.1002/mds.21507 · Cited by 3,027
Self-citationLitvan, I., Goldman, J. G., Tröster, A. I., Schmand, B. A., Weintraub, D., Petersen, R. C., Mollenhauer, B., Adler, C. H., Marder, K., Williams‐Gray, C. H., et al. (2012) · Movement Disorders · doi:10.1002/mds.24893 · Cited by 2,609
Self-citationThe Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years
Hely, M. A., Reid, W. G. J., ADENA, M. A., Halliday, G. M., & Morris, J. G. (2008) · Movement Disorders · doi:10.1002/mds.21956 · Cited by 2,346
α-synuclein locus duplication as a cause of familial Parkinson's disease
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17103-1 · Cited by 2,029
Healy, D. G., Falchi, M., O'Sullivan, S. S., Bonifati, V., Durr, A., Bressman, S., Brice, A., Aasly, J., Zabetian, C. P., Goldwurm, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70117-0 · Cited by 1,425
Prevalence and Characteristics of Dementia in Parkinson Disease
Aarsland, D., Andersen, K., Larsen, J. O., & Lolk, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.3.387 · Cited by 1,403
Self-citationMultimodal classification of Alzheimer's disease and mild cognitive impairment
Zhang, D., Wang, Y., Zhou, L., Yuan, H., & Shen, D. G. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.01.008 · Cited by 1,340
Cited by
Sorted by citations
The neuropathological diagnosis of Alzheimer's disease
DeTure, M. A., & Dickson, D. W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0333-5 · Cited by 3,329
“Moreover there are several candidate genetic risk factors that overlap for AD and PD, most notably APOE and MAPT [127].”
BackgroundHallmarks of Brain Aging: Adaptive and Pathological Modification by Metabolic States
Mattson, M. P., & Arumugam, T. V. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.05.011 · Cited by 1,242
Parkinson’s disease: etiopathogenesis and treatment
Jankovic, J. J., & Tan, E. K. (2020) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-322338 · Cited by 1,273
Allocati, N., Masulli, M., Di Ilio, C., & Federici, L. (2018) · Oncogenesis · doi:10.1038/s41389-017-0025-3 · Cited by 625
A Quarter Century of APOE and Alzheimer’s Disease: Progress to Date and the Path Forward
Belloy, M. E., Napolioni, V., & Greicius, M. D. (2019) · Neuron · doi:10.1016/j.neuron.2019.01.056 · Cited by 570
Are dementia with Lewy bodies and Parkinson’s disease dementia the same disease?
Jellinger, K. A., & Korczyn, A. D. (2018) · BMC Medicine · doi:10.1186/s12916-018-1016-8 · Cited by 406
Bee Venom: Overview of Main Compounds and Bioactivities for Therapeutic Interests
Wehbe, R., Frangieh, J., Rima, M., Obeid, D. E., Sabatier, J., & Fajloun, Z. (2019) · Molecules · doi:10.3390/molecules24162997 · Cited by 373
Dynamic functional connectivity changes associated with dementia in Parkinson’s disease
Fiorenzato, E., Strafella, A. P., Kim, J., Schifano, R., Weis, L., Antonini, A., & Biundo, R. (2019) · Brain · doi:10.1093/brain/awz192 · Cited by 311
Czubowicz, K., Jęśko, H. M., Wencel, P. L., Lukiw, W. J., & Strosznajder, R. P. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1448-3 · Cited by 303
Network connectivity determines cortical thinning in early Parkinson’s disease progression
Yau, Y. H. C., Zeighami, Y., Baker, T. E., Larcher, K. M.-H., Vainik, U., Dadar, M., Fonov, V., Hagmann, P., Griffa, A., Mišić, B., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02416-0 · Cited by 266
Dementia with Lewy bodies and Parkinson’s disease-dementia: current concepts and controversies
Jellinger, K. A. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1821-9 · Cited by 277
The Pharmacological Action of Kaempferol in Central Nervous System Diseases: A Review
dos Santos, J. S., Cirino, J. P. G., Carvalho, P. D. O., & Ortega, M. M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.565700 · Cited by 262
Structure–function coupling in macroscale human brain networks
Fotiadis, P., Parkes, L., Davis, K. A., Satterthwaite, T. D., Shinohara, R. T., & Bassett, D. S. (2024) · Nature reviews. Neuroscience · doi:10.1038/s41583-024-00846-6 · Cited by 280
18F-FDG PET in Parkinsonism: Differential Diagnosis and Evaluation of Cognitive Impairment
Meyer, P. T., Frings, L., Rücker, G., & Hellwig, S. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.186403 · Cited by 248
Microglia Response During Parkinson’s Disease: Alpha-Synuclein Intervention
Ferreira, S. A., & Romero‐Ramos, M. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00247 · Cited by 227
Wang, Y., Hu, J., Wu, S., Fleishman, J. S., Li, Y., Xu, Y.-S., Zou, W., Wang, J., Feng, Y., Chen, J., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01720-0 · Cited by 225
Schulz, J., Pagano, G., Bonfante, J. A. F., Wilson, H., & Politis, M. (2018) · Brain · doi:10.1093/brain/awy072 · Cited by 230
Self-citationCastelli, V., Benedetti, E., Antonosante, A., Catanesi, M., Pitari, G., Ippoliti, R., Cimini, A., & d’Angelo, M. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00132 · Cited by 224
Chidambaram, S. B., Essa, M. M., Rathipriya, A. G., Bishir, M., Ray, B., Mahalakshmi, A. M., Tousif, A. H., Sakharkar, M. K., Kashyap, R. S., Friedland, R. P., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107988 · Cited by 204
The Gut-Brain Axis in Parkinson’s Disease: Possibilities for Food-Based Therapies
Perez-Pardo, P., Kliest, T., Dodiya, H. B., Broersen, L. M., Garssen, J., Keshavarzian, A., & Kraneveld, A. D. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.042 · Cited by 203
“Although PD is generally considered as a movement disorder, it has long been recognized that the symptoms go beyond motor dysfunction since PD patients very often develop non-motor symptoms, including cognitive impairment (Aarsland et al., 2017), hyposmia (Haehner et al.”
Backgroundda Silva, F. C., Iop, R. D. R., de Oliveira, L. C., Boll, A. M., de Alvarenga, J. G. S., Gutierres Filho, P. J. B., de Melo, L. M. A. B., Xavier, A. J., & da Silva, R. (2018) · PLOS ONE · doi:10.1371/journal.pone.0193113 · Cited by 189
Phytochemicals and cognitive health: Are flavonoids doing the trick?
Bakoyiannis, I., Daskalopoulou, A., Pergialiotis, V., & Perrea, D. N. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.086 · Cited by 189
An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders
Ashton, N. J., Hye, A., Rajkumar, A. P., Leuzy, A., Snowden, S. G., Suárez‐Calvet, M., Karikari, T. K., Schöll, M., Joie, R. L., Rabinovici, G. D., et al. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0348-0 · Cited by 185
Self-citationLiu, G., Locascio, J. J., Corvol, J., Boot, B. P., Liao, Z., Page, K., Franco, D., Burke, K., Jansen, I. E., Lipsanopoulos, A. T. T., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30122-9 · Cited by 174
Rosario, D., Bidkhori, G., Lee, S., Bedarf, J., Hildebrand, F., Le Chatelier, E., Uhlen, M., Ehrlich, S. D., Proctor, G., Wüllner, U., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108807 · Cited by 167
Postural Instability in Parkinson’s Disease: A Review
Palakurthi, B., & Burugupally, S. P. (2019) · Brain Sciences · doi:10.3390/brainsci9090239 · Cited by 180
The Role of the Gut Microbiota in the Pathogenesis of Parkinson's Disease
Yang, D., Zhao, D., Ali Shah, S. Z., Wu, W., Lai, M., Zhang, X., Li, J., Guan, Z., Zhao, H., Li, W., et al. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01155 · Cited by 162
Acetylcholine bidirectionally regulates learning and memory
Huang, Q., Liao, C., Ge, F., Ao, J., & Liu, T. (2022) · Journal of Neurorestoratology · doi:10.1016/j.jnrt.2022.100002 · Cited by 181
Rai, S. N., Birla, H., Singh, S. S., Zahra, W., Patil, R. R., Jadhav, J. P., Gedda, M. R., & Singh, S. P. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00421 · Cited by 161
Network imaging biomarkers: insights and clinical applications in Parkinson's disease
Schindlbeck, K. A., & Eidelberg, D. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30169-8 · Cited by 163
Role of Oxidative Stress in Blood–Brain Barrier Disruption and Neurodegenerative Diseases
Kim, S., Jung, U. J., & Kim, S. R. (2024) · Antioxidants · doi:10.3390/antiox13121462 · Cited by 189
The Free-movement pattern Y-maze: A cross-species measure of working memory and executive function
Cleal, M., Fontana, B. D., Ranson, D. C., McBride, S. D., Swinny, J. D., Redhead, E. S., & Parker, M. O. (2020) · Behavior Research Methods · doi:10.3758/s13428-020-01452-x · Cited by 159
Strategies for the Treatment of Parkinson’s Disease: Beyond Dopamine
Iarkov, A., Barreto, G. E., Grizzell, J. A., & Echeverrı́a, V. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00004 · Cited by 146
Amyloid-β and Parkinson’s disease
Kings Parcog groupMDS Nonmotor study group, Lim, E. W., Aarsland, D., Ffytche, D. H., Taddei, R. N., van Wamelen, D. J., Wan, Y.-M., Tan, E. K., & Chaudhuri, К. R. (2018) · Journal of Neurology · doi:10.1007/s00415-018-9100-8 · Cited by 143
Self-citationInternational Multicenter Analysis of Brain Structure Across Clinical Stages of Parkinson's Disease
Laansma, M. A., Bright, J. K., Al–Bachari, S., Anderson, T., Ard, T. D., Assogna, F., Baquero, K., Berendse, H. W., Blair, J. C., Cendes, F., et al. (2021) · Movement Disorders · doi:10.1002/mds.28706 · Cited by 131
Self-citationLiu, G., Peng, J., Liao, Z., Locascio, J. J., Corvol, J.-C., Zhu, F., Dong, X., Maple-Grødem, J., Campbell, M. C., Elbaz, A., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00847-6 · Cited by 127
Diabetes and Cognitive Impairment: A Role for Glucotoxicity and Dopaminergic Dysfunction
Pignalosa, F. C., Desiderio, A., Mirra, P., Nigro, C., Perruolo, G., Ulianich, L., Formisano, P., Bèguinot, F., Miele, C., Napoli, R., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212366 · Cited by 130
Russell, M. W. W., Chung, W. K., Kaltman, J. R., & Miller, T. A. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.006906 · Cited by 128
Dysfunctional Limbic Circuitry Underlying Freezing of Gait in Parkinson’s Disease
Gilat, M., Martens, K. A. E., Miranda-Domínguez, Ó., Arpan, I., Shine, J. M., Mancini, M., Fair, D. A., Lewis, S. J. G., & Horak, F. B. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.01.044 · Cited by 123
Mild cognitive impairment in Parkinson’s disease: the Parkinson’s disease cognitive study (PACOS)
Monastero, R., Cicero, C. E., Baschi, R., Davì, M., Luca, A., Restivo, V., Zangara, C., Fierro, B., Zappia, M., & Nicoletti, A. S. Q. (2018) · Journal of Neurology · doi:10.1007/s00415-018-8800-4 · Cited by 122
Cognition-Oriented Treatments for Older Adults: a Systematic Overview of Systematic Reviews
Gavelin, H. M., Lampit, A., Hallock, H., Sabatés, J., & Bahar‐Fuchs, A. (2020) · Neuropsychology Review · doi:10.1007/s11065-020-09434-8 · Cited by 122
Innate and adaptive immune responses in Parkinson's disease
Schonhoff, A. M., Williams, G. P., Wallen, Z. D., Standaert, D. G., & Harms, A. S. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.10.006 · Cited by 119
Jung, N., Park, C., Kim, M., Lee, P., Sohn, Y., & Chang, J. W. (2019) · Journal of Neurosurgery · doi:10.3171/2018.2.jns172514 · Cited by 93
Cunningham, J. C., Broglio, S. P., O’Grady, M., & Wilson, F. (2020) · Journal of Athletic Training · doi:10.4085/1062-6050-297-18 · Cited by 130
Primary cilia and ciliary signaling pathways in aging and age-related brain disorders
Ma, R., Kutchy, N. A., Chen, L., Meigs, D. D., & Hu, G. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105607 · Cited by 114
The Relevance of Insulin Action in the Dopaminergic System
Fiory, F., Perruolo, G., Cimmino, I., Cabaro, S., Pignalosa, F. C., Miele, C., Bèguinot, F., Formisano, P., & Oriente, F. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00868 · Cited by 118
Current Status of microRNA-Based Therapeutic Approaches in Neurodegenerative Disorders
Paul, S., Bravo-Vázquez, L. A., Uribe, S. P., Reyes‐Pérez, P., & Sharma, A. K. (2020) · Cells · doi:10.3390/cells9071698 · Cited by 105
Wang, Y., Gao, L., Chen, J., Li, Q., Huo, L., Wang, Y., Wang, H., & Du, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.757161 · Cited by 107
White matter abnormalities in the corpus callosum with cognitive impairment in Parkinson disease
Bledsoe, I. O., Stebbins, G. T., Merkitch, D., & Goldman, J. G. (2018) · Neurology · doi:10.1212/wnl.0000000000006646 · Cited by 103
Therapy of Parkinson's Disease Subtypes
Marras, C., Chaudhuri, К. R., Titova, N., & Mestre, T. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00894-7 · Cited by 99
An overview of sleep and circadian dysfunction in Parkinson's disease
Mantovani, S., Smith, S. S., Gordon, R., & O’Sullivan, J. D. (2018) · Journal of Sleep Research · doi:10.1111/jsr.12673 · Cited by 105
Gray Matter Changes in Parkinson’s and Alzheimer’s Disease and Relation to Cognition
Krajčovičová, L., Klobušiaková, P., & Rektorová, I. (2019) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-019-1006-z · Cited by 96
Halim, A., Qu, K.-Y., Zhang, X.-F., & Huang, N. (2021) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c00490 · Cited by 98
Recent advances in Lewy body dementia: A comprehensive review
Prasad, S., Katta, M. R., Abhishek, S., Sridhar, R., Valisekka, S. S., Hameed, M., Kaur, J., & Walia, N. (2022) · Disease-a-Month · doi:10.1016/j.disamonth.2022.101441 · Cited by 100
Hölscher, C. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109952 · Cited by 104
Motoric Cognitive Risk Syndrome: Association with Incident Dementia and Disability
Doi, T., Shimada, H., Makizako, H., Tsutsumimoto, K., Verghese, J., & Suzuki, T. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170195 · Cited by 93
Meta-Analysis of Cognition in Parkinson’s Disease Mild Cognitive Impairment and Dementia Progression
Wallace, E. R., Segerstrom, S. C., van Horne, C. G., Schmitt, F. A., & Koehl, L. (2021) · Neuropsychology Review · doi:10.1007/s11065-021-09502-7 · Cited by 98
Treatment of Parkinson’s Disease with Cognitive Impairment: Current Approaches and Future Directions
Sun, C. E., & Armstrong, M. J. (2021) · Behavioral Sciences · doi:10.3390/bs11040054 · Cited by 95
Pimavanserin: Potential Treatment For Dementia-Related Psychosis
Cummings, J. L., Ballard, C. G., Tariot, P. N., Owen, R., Foff, E. P., Youakim, J. M., Norton, J., & Stankovic, S. (2018) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2018.29 · Cited by 92
Self-citationManenti, R., Cotelli, M. S., Cobelli, C., Gobbi, E., Brambilla, M., Rusich, D., Alberici, A., Padovani, A., Borroni, B., & Cotelli, M. (2018) · Brain stimulation · doi:10.1016/j.brs.2018.07.046 · Cited by 91
Nicoletti, A. S. Q., Luca, A., Baschi, R., Cicero, C. E., Mostile, G., Davì, M., Pilati, L., Restivo, V., Zappia, M., & Monastero, R. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00021 · Cited by 88
Homayoun, H. (2018) · Annals of Internal Medicine · doi:10.7326/aitc201809040 · Cited by 94
Singh, B., Covelo, A., Martell-Martinez, H. A., Nanclares, C., Sherman, M. A., Okematti, E., Meints, J. P., Teravskis, P. J., Gallardo, C., Savonenko, A. V., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02032-w · Cited by 85
Cognition in Parkinson's Disease
O’Callaghan, C., & Lewis, S. J. G. (2017) · International review of neurobiology · doi:10.1016/bs.irn.2017.05.002 · Cited by 90
Xiao, G., Song, Y., Zhang, Y., Xing, Y., Zhao, H., Xie, J., Xu, S., Gao, F., Wang, M., Xing, G., et al. (2019) · ACS Sensors · doi:10.1021/acssensors.9b00182 · Cited by 84
In Pursuit of Healthy Aging: Effects of Nutrition on Brain Function
Melzer, T. M., Manosso, L. M., Yau, S., Gil‐Mohapel, J., & Brocardo, P. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22095026 · Cited by 97
Hosseinzadeh, M., Gorji, A., Jouzdani, A. F., Rezaeijo, S. M., Rahmim, A., & Salmanpour, M. R. (2023) · Diagnostics · doi:10.3390/diagnostics13101691 · Cited by 85
Beta Amyloid Deposition Is Not Associated With Cognitive Impairment in Parkinson's Disease
Melzer, T. R., Stark, M. R., Keenan, R. J., Myall, D. J., MacAskill, M. R., Pitcher, T. L., Livingston, L., Grenfell, S., Horne, K., Young, B., et al. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00391 · Cited by 79
Zhang, Q., Hu, J., Wei, L., Jia, Y., & Jin, Y. (2019) · Complementary Therapies in Clinical Practice · doi:10.1016/j.ctcp.2019.04.005 · Cited by 80
Leta, V., Chaudhuri, К. R., Milner, O., Chung‐Faye, G., Metta, V., Pariante, C. M., & Borsini, A. (2021) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.07.026 · Cited by 79
Guo, J., Yue, F., Song, D., Bousset, L., Liang, X., Tang, J., Yuan, L., Li, W., Melki, R., Tang, Y. C., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-020-03369-x · Cited by 74
Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's Disease in Germany?
Heinzel, S., Berg, D., Binder, S., Ebersbach, G., Hickstein, L., Herbst, H., Lorrain, M., Wellach, I., Maetzler, W., Petersen, G., et al. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00500 · Cited by 75
Beyond Haemostasis and Thrombosis: Platelets in Depression and Its Co-Morbidities
Izzi, B., Tirozzi, A., Cerletti, C., Donati, M. B., de Gaetano, G., Hoylaerts, M., Iacoviello, L., & Gialluisi, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228817 · Cited by 79
Hirano, S. (2021) · Molecular Medicine · doi:10.1186/s10020-021-00301-7 · Cited by 72
Neuroimaging in Parkinson’s disease dementia: connecting the dots
Weil, R. S., Hsu, J. K., Darby, R. R., Soussand, L., & Fox, M. D. (2019) · Brain Communications · doi:10.1093/braincomms/fcz006 · Cited by 71
Gargouri, F., Galléa, C., Mongin, M., Pyatigorskaya, N., Valabrègue, R., Ewenczyk, C., Sarazin, M., Yahia‐Cherif, L., Vidailhet, M., & Lehéricy, S. (2018) · Movement Disorders · doi:10.1002/mds.27561 · Cited by 72
Jones, J. D., Rahmani, E., Garcia, E., & Jacobs, J. P. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.01.009 · Cited by 79
Vallée, A., Vallée, J.-N., & Lecarpentier, Y. (2021) · Cells · doi:10.3390/cells10020230 · Cited by 71
Computerized cognitive training in Parkinson’s disease: A systematic review and meta-analysis
Gavelin, H. M., Domellöf, M. E., Leung, I. H. K., Neely, A. S., Launder, N. H., Nategh, L., Finke, C., & Lampit, A. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101671 · Cited by 71
Feleke, R., Reynolds, R. H., Smith, A. M., Tilley, B. S., Taliun, S. A. G., Hardy, J., Matthews, P. M., Gentleman, S., Owen, D. R., Johnson, M. R., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02343-x · Cited by 69
Nosrani, E. A., Tamtaji, O. R., Alibolandi, Z., Sarkar, P., Ghazanfari, M., Tameh, A. A., Taghizadeh, M., Banikazemi, Z., Hadavi, R., & Taheri, M. N. (2020) · Journal of Immunoassay and Immunochemistry · doi:10.1080/15321819.2020.1833917 · Cited by 70
Redefining Non-Motor Symptoms in Parkinson’s Disease
Peña-Zelayeta, L., Delgado-Minjares, K. M., Villegas-Rojas, M. M., León‐Arcia, K., Santiago-Balmaseda, A., Andrade-Guerrero, J., Pérez-Segura, I., Ortega‐Robles, E., Soto-Rojas, L. O., & Arias-Carrión, Ó. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15050172 · Cited by 80
Rosário, D., Borén, J., Uhlén, M., Proctor, G., Aarsland, D., Mardinoğlu, A., & Shoaie, S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00716 · Cited by 66
Self-citationRadad, K., Moldzio, R., Krewenka, C., Kranner, B., & Rausch, W. (2023) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2023.00036 · Cited by 68
Neuromicrobiology: How Microbes Influence the Brain
de la Fuente‐Núñez, C., Meneguetti, B. T., Franco, O. L., & Lu, T. K. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00373 · Cited by 75
Assessment and Management of Neuropsychiatric Symptoms in Parkinson’s Disease
Mueller, C., Rajkumar, A. P., Wan, Y.-M., Velayudhan, L., Ffytche, D. H., Chaudhuri, К. R., & Aarsland, D. (2018) · CNS Drugs · doi:10.1007/s40263-018-0540-6 · Cited by 78
Self-citationQu, W., Yuan, B., Li, R., Liu, Q., Zhang, X., Cui, R., Yang, W., & Li, B. (2020) · Cell Proliferation · doi:10.1111/cpr.12959 · Cited by 65
Pan, W., Liu, P., Ma, D., & Yang, J. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-03988-w · Cited by 67
Lasaponara, S., Marson, F., Doricchi, F., & Cavallo, M. (2021) · Brain Sciences · doi:10.3390/brainsci11050528 · Cited by 72
The Pharmacological Potential of Adenosine A2A Receptor Antagonists for Treating Parkinson’s Disease
Mori, A., Chen, J., Uchida, S., Durlach, C., King, S. M., & Jenner, P. G. (2022) · Molecules · doi:10.3390/molecules27072366 · Cited by 67
Wang, Y., Wu, S., Li, Q., Lang, W., Li, W., Jiang, X., Wan, Z., Chen, J., & Wang, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.977521 · Cited by 73
Creese, B., Bell, E., Johar, I., Francis, P. T., Ballard, C. G., & Aarsland, D. (2017) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32549 · Cited by 68
Self-citationTherapeutic Potential of Ursolic Acid to Manage Neurodegenerative and Psychiatric Diseases
Ramos-Hryb, A. B., Pazini, F. L., Kaster, M. P., & Rodrigues, A. L. S. (2017) · CNS Drugs · doi:10.1007/s40263-017-0474-4 · Cited by 66
Adenzato, M., Manenti, R., Enrici, I., Gobbi, E., Brambilla, M., Alberici, A., Cotelli, M. S., Padovani, A., Borroni, B., & Cotelli, M. (2019) · Translational Neurodegeneration · doi:10.1186/s40035-018-0141-9 · Cited by 67
Zhang, R., Wang, S., Huang, X., Yang, Y., Fan, H., Yang, F., Li, J., Dong, X., Feng, S., Anbu, P., et al. (2019) · Analytica Chimica Acta · doi:10.1016/j.aca.2019.10.012 · Cited by 66
Garcia, P., Jürgens‐Wemheuer, W., Uriarte Huarte, O., Michelucci, A., Masuch, A., Brioschi, S., Weihofen, A., Koncina, E., Coowar, D., Heurtaux, T., et al. (2022) · Glia · doi:10.1002/glia.24149 · Cited by 65
Guo, Z., Ruan, Z., Zhang, D., Liu, X., Hou, L., & Wang, Q. (2021) · Chemosphere · doi:10.1016/j.chemosphere.2021.132982 · Cited by 66
Serotonin, β‐amyloid, and cognition in Parkinson disease
Kotagal, V., Spino, C., Bohnen, N. I., Koeppe, R., & Albin, R. L. (2018) · Annals of Neurology · doi:10.1002/ana.25236 · Cited by 64
Guo, Y., Liu, F., Hou, X., Li, J., Cao, X., Tan, L., Wang, J., & Yu, J. (2020) · Journal of Neurology · doi:10.1007/s00415-020-09757-9 · Cited by 68
Sampedro, F., Pérez‐González, R., Martínez‐Horta, S., Marín‐Lahoz, J., Pagonabarraga, J., & Kulisevsky, J. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.04.009 · Cited by 62
Metadata
- Authors
- Aarsland, D., Creese, B., Politis, M., Chaudhuri, K. R., ffytche, D. H., Weintraub, D., & Ballard, C.
- Affiliations
- King's College London (GB)
- Corresponding author
- Aarsland, Dag
- Venue
- Nature Reviews Neurology
- Published
- 2017-03-03
- Volume
- 13
- Issue
- 4
- Pages
- 217-231
- ISSN
- 1759-4758 (ISSN-L)
- 1759-4766
- PMC
- PMC5643027
- OpenAlex
- W2593272776
- Cited by
- 1,027
- References
- 216
- Citations by year
- 2026: 102 · 2025: 99 · 2024: 138 · 2023: 104 · 2022: 105 · 2021: 171 · 2020: 116 · 2019: 89 · 2018: 68 · 2017: 33
- FWCI
- 11.11
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Open Research Exeter (University of Exeter) (acceptedVersion)
- Figshare (submittedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Funders
- South London and Maudsley NHS Foundation Trust
- National Institute for Health and Care Research
- King's College London
- Institute of Psychiatry, Psychology and Neuroscience, King’s College London
- National Institute of Neurological Disorders and Stroke (P50NS053488)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Keywords
- Parkinson's disease, cognitive decline, Parkinson's disease dementia, mild cognitive impairment, cerebrospinal fluid biomarkers, amyloid-beta 42, Lewy body pathology, APOE ε4, GBA mutations, cognitive training, nootropic drugs
- MeSH terms
- Dementia, Humans, Parkinson Disease, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
